CN104813167B - 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 - Google Patents

用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 Download PDF

Info

Publication number
CN104813167B
CN104813167B CN201380061709.6A CN201380061709A CN104813167B CN 104813167 B CN104813167 B CN 104813167B CN 201380061709 A CN201380061709 A CN 201380061709A CN 104813167 B CN104813167 B CN 104813167B
Authority
CN
China
Prior art keywords
purposes
treatment
inhibitor
long
tumor marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380061709.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104813167A (zh
Inventor
谢燕玲
U·霍克
A·汉纳
M·A·埃尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN104813167A publication Critical patent/CN104813167A/zh
Application granted granted Critical
Publication of CN104813167B publication Critical patent/CN104813167B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380061709.6A 2012-11-28 2013-11-27 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法 Active CN104813167B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730900P 2012-11-28 2012-11-28
US61/730,900 2012-11-28
PCT/US2013/072205 WO2014085571A1 (en) 2012-11-28 2013-11-27 Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase i inhibitor

Publications (2)

Publication Number Publication Date
CN104813167A CN104813167A (zh) 2015-07-29
CN104813167B true CN104813167B (zh) 2019-04-09

Family

ID=49753531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061709.6A Active CN104813167B (zh) 2012-11-28 2013-11-27 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法

Country Status (10)

Country Link
US (2) US10132810B2 (OSRAM)
EP (1) EP2926137B1 (OSRAM)
JP (1) JP6284541B2 (OSRAM)
KR (1) KR102120510B1 (OSRAM)
CN (1) CN104813167B (OSRAM)
AU (1) AU2013352223B2 (OSRAM)
CA (1) CA2890082C (OSRAM)
ES (1) ES2731725T3 (OSRAM)
MX (1) MX366911B (OSRAM)
WO (1) WO2014085571A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106191022B (zh) * 2016-02-22 2019-08-20 叶尚勉 一种肿瘤特异抗原及其应用
JP7546552B2 (ja) 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
CN112102914A (zh) * 2020-09-25 2020-12-18 复旦大学附属肿瘤医院 曲妥珠单抗生物类似药的评价方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101420963A (zh) * 2006-02-09 2009-04-29 安佐制药股份有限公司 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
CN102164617A (zh) * 2008-09-23 2011-08-24 尼克塔治疗公司 在受试者体内实现持续的治疗药物浓度的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
SI1675622T1 (sl) * 2003-09-17 2017-09-29 Nektar Therapeutics Večkraka polimerna predzdravila
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US20050232927A1 (en) * 2004-02-03 2005-10-20 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2007025249A2 (en) * 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administration of oxytocin
WO2009059393A1 (en) 2007-11-06 2009-05-14 University Health Network Method for the detection of breast cancer by determining alcam and/or bcam levels in a patient sample
EA024533B1 (ru) 2009-11-18 2016-09-30 Нектар Терапьютикс Формы солей кислот конъюгатов полимер-лекарственное средство
CA2795776A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2012031320A1 (en) * 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
US20140378404A1 (en) 2011-10-25 2014-12-25 Nektar Therapeutics Treatment of Patients Suffering from Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101420963A (zh) * 2006-02-09 2009-04-29 安佐制药股份有限公司 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
CN102164617A (zh) * 2008-09-23 2011-08-24 尼克塔治疗公司 在受试者体内实现持续的治疗药物浓度的组合物和方法

Also Published As

Publication number Publication date
MX366911B (es) 2019-07-30
AU2013352223B2 (en) 2019-07-18
JP2016502083A (ja) 2016-01-21
CA2890082A1 (en) 2014-06-05
CA2890082C (en) 2021-07-06
ES2731725T3 (es) 2019-11-18
US10132810B2 (en) 2018-11-20
EP2926137A1 (en) 2015-10-07
KR20150089013A (ko) 2015-08-04
KR102120510B1 (ko) 2020-06-08
EP2926137B1 (en) 2019-05-29
US20150309032A1 (en) 2015-10-29
CN104813167A (zh) 2015-07-29
WO2014085571A1 (en) 2014-06-05
MX2015006733A (es) 2015-08-14
US20190049450A1 (en) 2019-02-14
JP6284541B2 (ja) 2018-02-28
AU2013352223A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
US20230074866A1 (en) Combination Therapy for Cancer Treatment
KR101313702B1 (ko) 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP3296319B1 (en) Methods for treating colorectal cancer
AU2011329681A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
WO2012027716A1 (en) Method to treat melanoma in braf inhibitor-resistant subjects
JP2010508277A (ja) 癌を検出および抑制するための方法
CN104813167B (zh) 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
US20190269666A1 (en) Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
US20230056846A1 (en) Methods and compositions for cancer immunotherapy
JP7311902B2 (ja) 前立腺がんの予防又は治療剤
Wu et al. Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer
WO2025060553A1 (zh) 马普替林与ctla4抗体联用在制备抗肿瘤药物中的应用
WO2018093668A1 (en) Therapy for metatastic colorectal cancer using anti-vegfr-2 and anti-vegf-d antibodies
TW202228772A (zh) 藉由併用阿替利珠單抗、托珠單抗、吉西他濱、白蛋白結合紫杉醇之4劑的胰臟癌治療劑
CN117327067B (zh) 一种小分子化合物epic-1042、药物组合物及其制备方法和应用
Guzman et al. P-264 Helicobacter pylori SNPs associated with tetracycline, clarithromycin and amoxicillin resistance in Colombia
Lanki Prognostic and differential diagnostic biomarkers in pancreatic ductal adenocarcinoma
TW201713362A (zh) 選擇性抑制腸羧酸酯酶2酵素活性的組成物及方法
CN116735877A (zh) Hdgf作为酪氨酸激酶抑制剂耐药靶点及相关应用
HK1252832B (en) Methods for treating colorectal cancer
KR20190073707A (ko) Ｂｒａｆ（ｖ６００ｅ） 돌연변이 역형성 갑상선암의 종양 억제능을 극대화할 수 있는 약학 조성물 및 약물 선택의 정보 제공 방법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant